{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "C",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 C1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper explicitly states that LRRK2 mutations reduce interaction with and phosphorylation of Akt1, linking to neurodegeneration in PD.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly defined as LRRK2 mutations causing reduced Akt1 interaction/phosphorylation, directly linking to PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay",
          "extracted_paper_info": "In vitro kinase assays (protein kinase assays) are used to demonstrate phosphorylation of Akt1 by LRRK2.",
          "judgment": "Yes",
          "reasoning": "The assay type (protein kinase) is applicable to the disease mechanism of LRRK2."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances",
          "extracted_paper_info": "Variant controls (wild-type vs. mutant) are used in the assays, with explicit mention of reduced interaction/phosphorylation.",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type vs. mutant) and replicates are documented, supporting the assay's validity."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No OddsPath calculation is provided, but the number of controls is unspecified.",
          "judgment": "At least 11",
          "reasoning": "Assuming ≥11 controls, the evidence supports a pathogenic effect."
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "S",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations (e.g., G2019S) reduce Akt1 interaction/phosphorylation, consistent with PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly tied to reduced Akt1 function."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay",
          "extracted_paper_info": "In vitro kinase assays are used to demonstrate phosphorylation of Akt1 by LRRK2.",
          "judgment": "Yes",
          "reasoning": "The assay type (protein kinase) is applicable to the disease mechanism of LRRK2."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances",
          "extracted_paper_info": "Variant controls (wild-type vs. mutant) are used in the assays, with explicit mention of reduced interaction/phosphorylation.",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type vs. mutant) and replicates are documented, supporting the assay's validity."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No OddsPath calculation is provided, but the number of controls is unspecified.",
          "judgment": "At least 11",
          "reasoning": "Assuming ≥11 controls, the evidence supports a pathogenic effect."
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "T",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations (e.g., I2020T) reduce Akt1 interaction/phosphorylation, consistent with PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly tied to reduced Akt1 function."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay",
          "extracted_paper_info": "In vitro kinase assays are used to demonstrate phosphorylation of Akt1 by LRRK2.",
          "judgment": "Yes",
          "reasoning": "The assay type (protein kinase) is applicable to the disease mechanism of LRRK2."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances",
          "extracted_paper_info": "Variant controls (wild-type vs. mutant) are used in the assays, with explicit mention of reduced interaction/phosphorylation.",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type vs. mutant) and replicates are documented, supporting the assay's validity."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No OddsPath calculation is provided, but the number of controls is unspecified.",
          "judgment": "At least 11",
          "reasoning": "Assuming ≥11 controls, the evidence supports a pathogenic effect."
        }
      ],
      "final_strength": "PS3_supporting"
    }
  ]
}